Ge X. et al. found that NFATc1 restricts the proliferation and chondrogenesis of osteochondroma precursors and NFATc2 preferentially inhibits chondrocyte hypertrophy and osteogenesis, which suggests that skeletal diseases characterized by defective or exaggerated osteochondral growth may be treated by regulating NFAT activity [26]. This evidence concerns the gene NFATC2 and bone disorder.